CA-125

Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer
Vinita M. Alexander, Alan N. Gordon, David H. Howard, Namita Khanna

International Journal of Gynecologic Cancer Sep 2017, 27 (7) 1333-1342; DOI: 10.1097/IGC.0000000000001040
Dynamic Prediction of Outcome for Patients With Ovarian Cancer: Application of a Joint Model for Longitudinal Cancer Antigen 125 Values
Yuting Cao, Yi Jiang, Xiao Lin, Jinsong Liu, Tao Lu, Wenjun Cheng, Fangrong Yan

International Journal of Gynecologic Cancer Jan 2018, 28 (1) 85-91; DOI: 10.1097/IGC.0000000000001134
Detecting Asymptomatic Recurrence in Early-Stage Endometrial Cancer: The Value of Vaginal Cytology, Imaging Studies, and CA-125
Jung-Yun Lee, Ji Hee Kim, Jung Won Seo, Hee Seung Kim, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song

International Journal of Gynecologic Cancer Oct 2016, 26 (8) 1434-1439; DOI: 10.1097/IGC.0000000000000797
CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer
Xiaoxiang Chen, Jing Zhang, Wenjun Cheng, Doo Young Chang, Jianfei Huang, Xuan Wang, Lizhou Jia, Daniel G. Rosen, Wei Zhang, Da Yang, David M. Gershenson, Anil K. Sood, Robert C. Bast, Jinsong Liu

International Journal of Gynecologic Cancer Jun 2013, 23 (5) 815-822; DOI: 10.1097/IGC.0b013e31828f7a24
"The Booklet Helped Me Not to Panic": A Pilot of a Decision Aid for Asymptomatic Women With Ovarian Cancer and With Rising CA-125 Levels
Caroline Anderson, Jonathan Carter, Kathryn Nattress, Philip Beale, Shannon Philp, James Harrison, Ilona Juraskova

International Journal of Gynecologic Cancer Apr 2011, 21 (4) 737-743; DOI: 10.1111/IGC.0b013e3181fe8b57
What Surveillance Plan Should Be Advised for Patients in Remission After Completion of First-Line Therapy for Advanced Ovarian Cancer?
Gordon J. S. Rustin

International Journal of Gynecologic Cancer Sep 2010, 20 (Suppl 2) S27-S28; DOI: 10.1111/IGC.0b013e3181f63a28
Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 Levels
Priya Bhosale, Silanath Peungjesada, Wei Wei, Charles F. Levenback, Kathleen Schmeler, Eric Rohren, Homer A. Macapinlac, Revathy B. Iyer

International Journal of Gynecologic Cancer Jul 2010, 20 (6) 936-944; DOI: 10.1111/IGC.0b013e3181e82a7f
CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
Ana Oaknin, Pilar Barretina, Xavier Pérez, Laura Jimenez, Montserrat Velasco, Maria Alsina, Joan Brunet, Josep Ramon GermÀ, Miguel Beltran

International Journal of Gynecologic Cancer Jan 2010, 20 (1) 87-91; DOI: 10.1111/IGC.0b013e3181c16ba1
A Proteomics Panel for Predicting Optimal Primary Cytoreduction in Stage III/IV Ovarian Cancer
Signe Risum, Estrid Høgdall, Svend A. Engelholm, Eric Fung, Lee Lomas, Christine Yip, Anette L. Petri, Lotte Nedergaard, Lene Lundvall, Claus Høgdall

International Journal of Gynecologic Cancer Nov 2009, 19 (9) 1535-1538; DOI: 10.1111/IGC.0b013e3181a840f5
Preoperative Diagnosis of Ovarian Malignancy: Preliminary Results of the Use of 3-Dimensional Vascular Ultrasound
Dana M. Chase, Michael Crade, Tania Basu, Bahman Saffari, Michael L. Berman

International Journal of Gynecologic Cancer Mar 2009, 19 (3) 354-360; DOI: 10.1111/IGC.0b013e3181a1d73e

Main menu

CA-125

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

CA-125

Pages